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Hepatocellular carcinoma is one of the most serious complications of chronic liver disease and is the third most lethal cancer
worldwide. Symptoms emerge very late in the course of its natural history with an attendant poor outcome. Screening is of
paramount importance in a successful strategy to treat hepatocellular carcinoma. A successful screening program rests the
availability of an at-risk population, reliable diagnostics tests that are able to diagnose a condition at a stage where eﬀective, and
relatively simple and acceptable treatments are available. In hepatocellular carcinoma, all patients with liver cirrhosis or chronic
hepatitis B virus infection are at risk. Six monthly ultrasound and alpha-foetoprotein determination form the backbone of the
screening program. Newer modalities and tests show promise but have not supplanted the standard tests.
1.Introduction
One of the most serious complications of chronic liver
disease is hepatocellular carcinoma. Across the world, it
is the 4th most common cancer (age standardised rate of
16 per 100,000) and the 3rd most common cause (age
standardised rate of 14.6 per 100,000) of deaths from all
cancers, accounting for 700,000 deaths per annum [1].
Although a global cancer, it is especially prevalent in the Asia
Paciﬁc and sub-Saharan Africa.
Theoutcomeofapatientafterthediscoveryofhepatocel-
lularcarcinoma,likemanymalignancies,verymuchdepends
on the stage of the disease at the time of diagnosis. Curative
treatment can be oﬀered to 30% of cases if diagnosed at
BCLC stage 0 or A and carries a 5-year survival of 40% to
70%. If diagnosed at stages B or C, the median survival with
treatment is 11–20 months. At stage D, only symptomatic
treatment is possible and survival does not exceed 3 months
[2]. Unfortunately, the lack of symptoms for most part of
the natural history of hepatocellular carcinoma is such that
many cases are discovered at late stages, limiting the survival
of these cases. It is the leading cause of mortality in patients
with compensated liver cirrhosis [3].
One of the main strategies for prolonging survival in
patients with chronic liver disease therefore lies in the
diagnosing hepatocellular carcinoma in the early stages so
that eﬀective therapy can be oﬀered. In this regard, screening
for hepatocellular carcinoma, that is, detection before the
onset of symptoms, forms the backbone of such a strategy.
2. Screeningfor Diseases
Screening refers to the detection of a condition whilst it
is still without sign or symptom. The repeated application
of screening is termed surveillance. The primary aim of
screening is to pick up a disease at a stage where treatment
is more eﬀective and the outcome, usually measured as
survival, is better compared with a later stage of discovery
of the condition. The World Health Organisation in 1968
published the following desirable criteria for a condition to
be screened [4].
(1) The condition should be an important health prob-
lem.
(2) There should be treatment for the condition.
(3) Facilities fordiagnosis and treatmentshouldbe avail-
able.
(4) There should be a test or examination for the condi-
tion.
(5) The test should be acceptable to the population.2 International Journal of Hepatology
(6) The natural history of the condition should be ade-
quately understood.
(7) There should be an agreed policy on who to treat.
(8) The total cost of ﬁnding the case should be economi-
cally balanced in relation to medical expenditure as a
whole.
(9) Case ﬁnding should be a continuous process, not just
a “once and for all” project.
Paraphrasing the above, the ideal screening programme
should meet the following criteria:
(1) a suﬃciently high prevalence of the disease in the
population to be screened;
(2) a reliable method for screening, that is, it should have
a high true positive rate or low false negative rate
(high sensitivity) and a high true negative rate or low
false positive rate (high speciﬁcity);
(3) the method of screening should also be easily avail-
able, inexpensive, and carries little or no risk of harm
to the individual screened;
(4) an eﬀective treatment should be available for the
disease to positively impact on the survival of the in-
dividual.
Currently the hepatocellular carcinoma screening pro-
grammes advocated by various expert bodies have a high
degree of concurrence. The ensuing discussion will review
the merits of hepatocellular carcinoma screening vis-` a-vis
the desired characteristics of an ideal screening programme
as listed above.
3. Prevalence of Hepatocellular Carcinoma
Hepatocellular carcinoma develops almost exclusively in the
setting of chronic liver disease. The risk of developing hep-
atocellular carcinoma in this group is over 200 times that of
the general population [5] .T h er i s kf a c t o r sa r el i v e rc i r r h o -
sis (where the repeated inﬂammation-necrosis-regeneration
cycle increases the risk of carcinogenesis) and chronic hep-
atitis B virus infection (where the incorporation of hepatitis
B virus genome into the hepatocyte DNA increases the
risk of carcinogenesis). The risk of hepatocellular carcinoma
development varies across these conditions and depends on
several factors: age, gender, presence of family history of
hepatocellular carcinoma, exposure to environmental factors
such as aﬂatoxins, and aetiology of cirrhosis [6]. Hepatitis
C-related cirrhosis appears to be associated with the highest
risk of hepatocellular carcinoma, with a 5-year cumulative
risk of 17–30%. Haemochromatosis-related cirrhosis carries
a 5-year cumulative incidence of 21% whereas hepatitis B-
related cirrhosis has a 5-year cumulative incidence of 10–
15% depending on endemicity. The corresponding ﬁgures
foralcoholiccirrhosisandadvancedprimarybiliarycirrhosis
are 8% and 4%, respectively [3]. Individuals with chronic
hepatitis B virus infections without cirrhosis have a 0.5%
annual risk of hepatocellular carcinoma. In this group the
risk is higher with advancing age, in men and in those with
a family history of hepatocellular carcinoma. Women are at
lower risk but the risk is increased in women above the age
of 50 years old [7, 8]. Chronic hepatitis B patients with liver
cirrhosis have an annual risk of hepatocellular carcinoma of
3–8%. In patients with liver cirrhosis caused by hepatitis C
virus infection or advanced primary biliary cirrhosis (stage
4), the annual risk of hepatocellular carcinoma is also high at
3–8%. Cirrhosis caused by other aetiologies such as genetic
haemochromatosis and alpha-1-antitrypsin deﬁciency carry
with it a lower annual risk of hepatocellular carcinoma of
around 1.5% [9–13]. It is clear that hepatocellular carcinoma
can develop from cirrhosis arising from nonalcoholic fatty
liver disorder. However the incidence is not clear [14, 15].
The eﬀectiveness of a screening strategy can be measured
by improvement in survival against the cost incurred to
achieve this outcome (cost for each year of life gained).
Other outcome measures such as quality of life gained, years
of economically viable life gained are important but are
more diﬃcult to assess. The thresholds for each of these
measures will vary according to cultures, individual outlook,
and economic status of a country and are arbitrary.
Utilising the principles of decision analysis and costef-
fectiveness, the generally accepted threshold for life gain is
3 months, achieved at a cost of less than US $50,000 per
year of life gained. Applying this to decide on the threshold
for screening hepatocellular carcinoma, the annual incidence
for screening noncirrhotic patients is to be 0.2% and above,
and for cirrhotic patients, this translates to an annual risk of
1.5% and above. The diﬀerence in the threshold incidences
betweennoncirrhosisandcirrhosisliesinthelowerquantum
of life gain when hepatocellular carcinoma is diagnosed in an
individual with liver cirrhosis.
Based on the above assumptions and thresholds, there
is no justiﬁcation for population-wide screening of hep-
atocellular carcinoma. Current screening strategies centre
on selecting high risk groups for screening [16]. The at-
risk groups meeting the above cost-eﬀective criteria for
hepatocellular carcinoma screening are
(1) patients with liver cirrhosis;
(2) male patients with chronic hepatitis B virus infection
without cirrhosis who are above the age of 40 years;
(3) female patients with chronic hepatitis B virus infec-
tion without cirrhosis who are above the age of 50
years;
(4) patients with chronic hepatitis B virus infection who
have a family history of hepatocellular carcinoma.
For younger individuals with chronic hepatitis B virus
infection, the annual risk of hepatocellular carcinoma
development is lower than the threshold of 0.2%, but the
disease is often more aggressive [17]. Whether the above
thresholds should be used to decide if screening should be
recommended for this group should be discussed. Whilst not
“costeﬀective”, the discovery of an early tumour in this age
group brings about the greatest potential gain in terms of
survival and also economically useful years gained, not to
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averting the trauma for the patient and family of coming to
terms with a fatal cancer in a young individual.
The risk of HCC in patients with chronic HBV infection
canalsobefurtherstratiﬁedusingprognosticvariables—age,
gender, indices of necroinﬂammation—alanine transami-
nase level, and HBV DNA load. A prognostic scoring system
wasdevelopedandvalidatedinalargeAsianpopulation with
chronic HBV and gives the risk of HCC development at 3, 5,
and 10 years [18]. This scoring system has the potential to be
applied to reﬁne the decision-making process with respect
to screening in less clear-cut situations, for example, in the
group discussed above.
4. Reliable Method of Screening
Currently available methods to diagnose hepatocellular car-
cinoma comprise blood tests to detect elevation of “tumour
markers” and imaging modalities. Blood tests that are
elevated with hepatocellular carcinoma include AFP (alpha-
fetoprotein), the more speciﬁc AFP-L3 (L3 subfraction of
AFP), and DCP (descarboxy prothrombin) [19–21]. AFP is
released by regenerating hepatocytes, malignant hepatocytes,
andalsoextrahepaticsourcessuchasplacentalcellsandgerm
cells. Among the nonmalignant causes that cause elevated
AFP are inﬂammatory liver conditions, pregnancy, and
molar pregnancy. The AFP-L3 is the glycosylated subfraction
of AFP and is speciﬁc to malignant hepatocytes. It is useful
in discriminating between AFP elevation arising from a
benign condition against that arising from hepatocellular
carcinoma. However its sensitivity is low in cases where the
AFP is not markedly elevated.
DCP is also speciﬁc to hepatocellular carcinoma; it is
found especially elevated when there is invasion of vascular
structures and is a marker of more advanced hepatocellular
carcinoma, and therefore may not be a suitable screening
tool.
AFP, taken at a level of 20ng/mL, has a sensitivity of
66% and a speciﬁcity of 82% for hepatocellular carcinoma.
AFP-L3 has not been studied adequately for screening of
hepatocellular carcinoma. Whilst speciﬁc, it will likely suﬀer
from decreased sensitivity and is not recommended as a
general screening tool. More recently the highly sensitive
AFP-L3(hs-AFP-L3)wasevaluatedinindividualswhoseAFP
was <20ng/mL [22]. It was found to increase the sensitivity
of detecting HCC from 7% with AFP-L3 to 41.5% with
hs-AFP-L3. In addition, it also predicted poorer outcomes
in patients with HCC. At present AFP-L3 and hs-AFP-L3
remain adjunctive tools in further evaluation in cases of
raisedAFPandisnotinapositiontosupplanttheuseofAFP
as a screening tool. As it stands, the present accepted blood
test for screening is AFP.
Liver imaging modalities that have proven eﬀective in
detecting hepatocellular carcinoma are ultrasound, CT scan,
and MRI scan of the liver. In trained operators, ultrasound
reliably detects liver nodules above the dimensions of 5mm.
Hepatocellular carcinoma may appear hypoechoic but may
be isoechoic or hyperechoic. Other pathological conditions
may share similar ultrasonic characteristics. Ultrasound has
a sensitivity of 65–80% and a speciﬁcity of 90% [16]. It is a
test that is generally reproducible, does not carry any adverse
eﬀects,andiseconomical.Onelimitationofultrasonography
is the diﬃculty in obtaining a good study in obese patients.
CT scan of the liver and MRI of the liver provide
diagnostic details superior to ultrasound. CT scan is now
w i d e l ya v a i l a b l e .I t sc o s th a sd e c r e a s e dw i t he c o n o m i e s
of scale. However, the radiation exposure is signiﬁcant,
raising the risk of carcinogenesis if used repeatedly [17].
Whilst advocated by some for screening of hepatocellular
carcinoma, it is still not yet accepted and therefore not
recommended for screening. MRI oﬀers superior resolution.
Whilst it does not have the drawback of radiation danger, it
is an expensive test, and the acquisition time for one study is
considerable, limiting its use as a screening test. At present
the use of wither MRI or CT scan of the liver lies in the
diagnosis of hepatocellular carcinoma where the screening
tests (either ultrasound or AFP) have ﬂagged up suspicion.
AtpresentthecombineduseofAFPandultrasoundisthe
recommended mode for screening. The interval of screening
should be such that the growth of cancer should be picked
up between 2 screening. Too short an interval is a waste
of healthcare resources and inconveniences the patient. Too
long an interval, in the other hand, runs the risk of allowing
the cancer to grow to a later stage, thereby compromising
the eﬀectiveness of the whole screening process. The deter-
minant of this interval is the rate of growth or doubling time
ofthecancer.StudiesinvolvingHCVpatientssuggestthat12-
monthscreeningintervalbringsaboutsurvivalimprovement
and is not diﬀerent from screening at 6-monht intervals [23,
24]. In studies of HBV patients, 6-month screening resulted
in improved survival compared to 12-month screening
[25].
5. Availabilityof Effective Therapy
The last 10–15 years have witnessed the advent of newer
treatment options for hepatocellular carcinoma, and with it,
somemeasureimprovementinoutcomes.Withearlydiagno-
sis, cure is possible in 30% of cases, and in the rest, eﬀective
controlisachievable.Surgicalresectionandlocalablationare
eﬀective in the treatment of an early, localised hepatocellular
carcinoma, and achieving 5-year survival of up to 70%.
Liver transplant in well-selected patients can bring about a
5-year survival in the order of 80% [26, 27]. Recent data
indicates that RFA is comparable to surgical resection for
earlyhepatocellularcarcinomain termsof survivaloutcomes
and has the advantage of being less invasive [28, 29].
Transarterial chemoembolisation is an option proven to
prolongsurvivalincasesofnonresectable,nontransplantable
cases of nonmetastatic hepatocellular carcinoma.
6. Summary
Surveillance of hepatocellular carcinoma is justiﬁed in
groups at risk of hepatocellular carcinoma. It allows for its
detection at earlier stages. This in turn translates to more
eﬀective treatment options resulting in improved survival.
HCC screening therefore is an important part of the strategy
in improving survival in patients with advanced liver disease.4 International Journal of Hepatology
Present screening method is that of AFP and ultrasound
performed at 6–12-month intervals.
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